Trevi Therapeutics (TRVI) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

TRVI Stock Forecast


Trevi Therapeutics stock forecast is as follows: an average price target of $6.00 (represents a 33.33% upside from TRVI’s last price of $4.50) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

TRVI Price Target


The average price target for Trevi Therapeutics (TRVI) is $6.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 33.33% upside from TRVI's last price of $4.50.

TRVI Analyst Ratings


Buy

According to 6 Wall Street analysts, Trevi Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for TRVI stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Trevi Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 22, 2024Oren LivnatH.C. Wainwright$6.00$3.3579.10%33.33%
Oct 04, 2024Mayank MamtaniB.Riley Financial$6.00$3.0298.68%33.33%
Jul 09, 2022Leland GershallOppenheimer$12.00$3.95203.80%166.67%

The latest Trevi Therapeutics stock forecast, released on Oct 22, 2024 by Oren Livnat from H.C. Wainwright, set a price target of $6.00, which represents a 79.10% increase from the stock price at the time of the forecast ($3.35), and a 33.33% increase from TRVI last price ($4.50).

Trevi Therapeutics Price Target by Period


1M3M12M
# Anlaysts-22
Avg Price Target-$6.00$6.00
Last Closing Price$4.50$4.50$4.50
Upside/Downside-100.00%33.33%33.33%

In the current month, the average price target of Trevi Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Trevi Therapeutics's last price of $4.50. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 22, 2024H.C. WainwrightBuyBuyHold
Aug 30, 2024Raymond JamesOutperformInitialise
Aug 30, 2024H.C. WainwrightBuyInitialise
Aug 19, 2024EF HuttonBuyInitialise
Jun 12, 2024Rodman & RenshawBuyInitialise
Nov 11, 2022NeedhamBuyBuyHold
Jun 30, 2022OppenheimerOutperformOutperformHold
Jun 29, 2022NeedhamBuyBuyHold
May 25, 2022OppenheimerOutperformInitialise

Trevi Therapeutics's last stock rating was published by H.C. Wainwright on Oct 22, 2024. The company gave TRVI a "Buy" rating, the same as its previous rate.

Trevi Therapeutics Financial Forecast


Trevi Therapeutics Revenue Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------------------
Avg Forecast$67.56M$63.74M$62.46M$61.19M---------------
High Forecast$67.56M$63.74M$62.46M$61.19M---------------
Low Forecast$67.56M$63.74M$62.46M$61.19M---------------
# Analysts1111---------------
Surprise %-------------------

Trevi Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. TRVI's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Trevi Therapeutics EBITDA Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts1111---------------
EBITDA-------------------
Avg Forecast-------------------
High Forecast-------------------
Low Forecast-------------------
Surprise %-------------------

undefined analysts predict TRVI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Trevi Therapeutics's previous annual EBITDA (undefined) of $NaN.

Trevi Therapeutics Net Income Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts1111---------------
Net Income-------------------
Avg Forecast$32.01M$30.75M$30.69M$30.11M$-5.08M$-4.59M$-4.25M$-4.49M$-7.13M$-6.43M$-5.97M$-6.29M$-12.93M$-11.56M$-11.77M$-11.86M$-11.92M$-12.08M$-10.97M
High Forecast$32.01M$30.75M$30.69M$30.11M$-5.08M$-4.59M$-4.25M$-4.49M$-7.13M$-6.43M$-5.97M$-6.29M$-12.93M$-11.56M$-11.77M$-10.87M$-10.93M$-12.08M$-10.97M
Low Forecast$32.01M$30.75M$30.69M$30.11M$-5.08M$-4.59M$-4.25M$-4.49M$-7.13M$-6.43M$-5.97M$-6.29M$-12.93M$-11.56M$-11.77M$-13.83M$-12.92M$-12.08M$-10.97M
Surprise %-------------------

Trevi Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TRVI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Trevi Therapeutics SG&A Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts1111---------------
SG&A-------------------
Avg Forecast-------------------
High Forecast-------------------
Low Forecast-------------------
Surprise %-------------------

Trevi Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to TRVI last annual SG&A of $NaN (undefined).

Trevi Therapeutics EPS Forecast

Dec 28Sep 28Jun 28Mar 28Dec 27Sep 27Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts1111---------------
EPS-------------------
Avg Forecast$0.32$0.30$0.30$0.30$-0.05$-0.05$-0.04$-0.04$-0.07$-0.06$-0.06$-0.06$-0.13$-0.11$-0.12$-0.12$-0.12$-0.12$-0.11
High Forecast$0.32$0.30$0.30$0.30$-0.05$-0.05$-0.04$-0.04$-0.07$-0.06$-0.06$-0.06$-0.13$-0.11$-0.12$-0.11$-0.11$-0.12$-0.11
Low Forecast$0.32$0.30$0.30$0.30$-0.05$-0.05$-0.04$-0.04$-0.07$-0.06$-0.06$-0.06$-0.13$-0.11$-0.12$-0.14$-0.13$-0.12$-0.11
Surprise %-------------------

According to undefined Wall Street analysts, Trevi Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TRVI previous annual EPS of $NaN (undefined).

Trevi Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
SPROSpero Therapeutics$1.04$10.00861.54%Buy
CCCCC4 Therapeutics$4.05$20.00393.83%Buy
ANEBAnebulo Pharmaceuticals$1.31$6.00358.02%Buy
PRLDPrelude Therapeutics$0.89$4.00349.44%Sell
BCABBioAtla$1.31$5.00281.68%Buy
ANTXAN2 Therapeutics$1.34$5.00273.13%Buy
CHRSCoherus BioSciences$1.71$6.00250.88%Hold
CGEMCullinan Oncology$11.49$34.00195.91%Buy
CUECue Biopharma$1.06$3.00183.02%Buy
LYRALyra Therapeutics$0.18$0.50177.78%Hold
FHTXFoghorn Therapeutics$5.51$14.00154.08%Buy
ORICORIC Pharmaceuticals$8.25$20.00142.42%Buy
BOLTBolt Biotherapeutics$0.54$1.0085.19%Hold
RZLTRezolute$4.44$6.6750.23%Buy
TRVITrevi Therapeutics$4.50$6.0033.33%Buy

TRVI Forecast FAQ


Is Trevi Therapeutics a good buy?

Yes, according to 6 Wall Street analysts, Trevi Therapeutics (TRVI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of TRVI's total ratings.

What is TRVI's price target?

Trevi Therapeutics (TRVI) average price target is $6 with a range of $6 to $6, implying a 33.33% from its last price of $4.5. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Trevi Therapeutics stock go up soon?

According to Wall Street analysts' prediction for TRVI stock, the company can go up by 33.33% (from the last price of $4.5 to the average price target of $6), up by 33.33% based on the highest stock price target, and up by 33.33% based on the lowest stock price target.

Can Trevi Therapeutics stock reach $7?

TRVI's average twelve months analyst stock price target of $6 does not support the claim that Trevi Therapeutics can reach $7 in the near future.

What are Trevi Therapeutics's analysts' financial forecasts?

Trevi Therapeutics's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-18.41M (high $-18.41M, low $-18.41M), average SG&A $0 (high $0, low $0), and average EPS is $-0.182 (high $-0.182, low $-0.182). TRVI's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $254.95M (high $254.95M, low $254.95M), average EBITDA is $0 (high $0, low $0), average net income is $123.55M (high $123.55M, low $123.55M), average SG&A $0 (high $0, low $0), and average EPS is $1.22 (high $1.22, low $1.22).